-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: March 2011
U.S. Inter-Agency Group takes on Counterfeit Pharmaceuticals
The Office of the Intellectual Property Enforcement Coordinator released an Inter-Agency report partnering with the Food and Drug Administration, U.S. Customs and Border Protection, U.S. Immigration and Customs Enforcement, and the Departments of Justice, State, and Commerce and USAID. The report highlights the Administration’s efforts to combat counterfeit pharmaceuticals listing various Department initiatives and in some cases providing actual budget numbers (State Department budgets $1.3 million in 2011 to combat counterfeit pharmaceuticals). Finally, the report Read More >
Patently BIOtech
1 Comment
Email This Post
Tags: CBP, congress, counterfeit, counterfeit drugs, counterfeit pharmaceuticals, Counterfeits, Department of Commerce, Department of Justice, Department of State, FDA, Food and Drug Administration, Inter-Agency, IP Czar, Joe Biden, mandatory disclosure, Office of the Intellectual Property Enforcement Coordinator, State Department, U.S. Customs and Border Protection, U.S. Immigration and Customs Enforcement, USAID, Vice President, Victoria Espinel
Tags: CBP, congress, counterfeit, counterfeit drugs, counterfeit pharmaceuticals, Counterfeits, Department of Commerce, Department of Justice, Department of State, FDA, Food and Drug Administration, Inter-Agency, IP Czar, Joe Biden, mandatory disclosure, Office of the Intellectual Property Enforcement Coordinator, State Department, U.S. Customs and Border Protection, U.S. Immigration and Customs Enforcement, USAID, Vice President, Victoria Espinel
Anitbody Deals Peaked in 2007
Antibody and antibody-like scaffold molecules have been on the pharma licensing radar for some time. The pharma business development interest in these drug candidates stems largely from the targeted mechanisms of action, structural uniqueness of the molecules, strong IP, and portfolio diversification benefits. To analyze deal trends in this niche area of biotechnology, we screened the Windhover/Elsevier Strategic Transactions Database for “Biotechnology” deals, with “Antibody” or “Large Molecule” identifiers, from 2007-2010. From this initial list, Read More >
BIO Poised to Partner with Chinese Leaders to Grow Biotech
This month, BIO is leading a delegation of biopharma CEOs to China for meetings with members of the Chinese biotech community and government leaders. The mission illustrates a strong commitment on behalf of the western biotechnology industry to encourage China to strengthen its support for biotech innovation and take steps to enhance greater investment and collaboration with companies in China. The series of meetings between China’s local industry and government leaders and biotech CEOs will Read More >
BIO Hails Senate Passage of America Invents Act
BIO Hails Senate Passage of America Invents Act Bipartisan, consensus-oriented approach will strengthen nation’s patent system and spur innovation, job creation Washington, D.C. (March 8, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the passage today of the America Invents Act (S. 23) by the U.S. Senate: “BIO commends the Senate for its overwhelming passage of the America Invents Act by a vote of 95-5. We appreciate Read More >
A Partner in Partnering: BIO and the China Healthcare Investment Conference
If you’re attending the China Healthcare Investment Conference this month, you’ll probably notice something familiar. BIO has partnered with the Lychee Group to use the One-on-One Partnering System during their event! The event focuses on the most influential Chinese and global thought leaders to promote the development of the Chinese healthcare market, and all attendees will now be able to send requests, schedule meetings, and connect with one another in private meetings. As with all Read More >
